• Zoetis recently expanded the capabilities of its AI-powered Vetscan OptiCell hematology analyzer, while investors and analysts have turned their attention to its upcoming May 7 earnings release and evolving product portfolio.
• The combination of point-of-care diagnostics innovation and heightened expectations around earnings and companion animal growth is sharpening focus on how Zoetis’ business mix may be evolving.
• We’ll now examine how the Vetscan OptiCell upgrade could influence Zoetis’ investment narrative built around innovation and recurring revenue.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Zoetis Investment Narrative Recap

To be a shareholder in Zoetis, you need to believe that companion animal health, diagnostics and recurring revenue will remain the core long term engine of the business, even as competition and OA pain concerns linger. The Vetscan OptiCell upgrade reinforces that diagnostics pillar, but it is unlikely to outweigh how the May 7 earnings update shapes sentiment around growth in key franchises and the near term risk of further pressure on OA pain adoption.

The most relevant recent development alongside the OptiCell news is Zoetis’ guidance for 2026 revenue of US$9.825 billion to US$10.025 billion and continued buybacks. That outlook, issued before this diagnostics enhancement, already framed expectations for modest organic growth and strong free cash flow. Investors now have to weigh whether expanding point of care diagnostics like OptiCell can meaningfully support that revenue range if competitive pressures in parasiticides and dermatology intensify.

Yet behind the appeal of innovation and recurring revenue, investors should be aware that growing competitive pressure in key franchises could...

Zoetis' narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and roughly a $0.6 billion earnings increase from $2.6 billion today.

Uncover how Zoetis' forecasts yield a $151.00 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a much tougher picture for Zoetis, assuming revenue of only about US$10.6 billion and earnings of US$3.2 billion by 2029, and warning that rising regulatory scrutiny could still bite harder than today’s optimism around AI diagnostics suggests.

Explore 9 other fair value estimates on Zoetis - why the stock might be worth as much as 86% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.